| Company Name: |
3B Pharmachem (Wuhan) International Co.,Ltd.
|
| Tel: |
821-50328103-801 18930552037 |
| Email: |
3bsc@sina.com |
| Products Intro: |
Product Name:CGP 52411;5,6-Bis(phenylaMino)-1H-isoindole-1,3(2H)-dione CAS:145915-58-8 Purity:99% HPLC Package:1Mg ; 5Mg;10Mg ;100Mg;250Mg ;500Mg ;1g;2.5g ;5g ;10g
|
DAPH manufacturers
- CGP52411
-
- $35.00 / 1mg
-
2026-05-11
- CAS:145915-58-8
- Min. Order:
- Purity: 99.78%
- Supply Ability: 10g
- CGP52411
-
- $35.00 / 1mg
-
2026-04-22
- CAS:145915-58-8
- Min. Order:
- Purity: 99.78%
- Supply Ability: 10g
|
| Product Name: | DAPH | | Synonyms: | DAPH-1
(DAPH;DAPH/CGP 52411;4,5-Dianilinophthalimide, 5,6-Bis(phenylamino)-1H-isoindole-1,3(2H)-dione, CGP 52411;1H-Isoindole-1,3(2H)-dione, 5,6-bis(phenylamino)-;DAPH >=98% (HPLC), solid;CGP52411, 10 mM in DMSO | | CAS: | 145915-58-8 | | MF: | C20H15N3O2 | | MW: | 329.35 | | EINECS: | 406-050-3 | | Product Categories: | | | Mol File: | 145915-58-8.mol |  |
| Melting point | 199-202℃ | | density | 1.374 | | storage temp. | 2-8°C | | solubility | DMSO: ~30 mg/mL | | pka | 9.06±0.20(Predicted) | | form | solid | | color | orange | | InChI | 1S/C20H15N3O2/c24-19-15-11-17(21-13-7-3-1-4-8-13)18(12-16(15)20(25)23-19)22-14-9-5-2-6-10-14/h1-12,21-22H,(H,23,24,25) | | InChIKey | AAALVYBICLMAMA-UHFFFAOYSA-N | | SMILES | O=C1NC(=O)c2cc(Nc3ccccc3)c(Nc4ccccc4)cc12 |
| Safety Statements | 36/37 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| Uses | CGP 52411 is a protein-tyrosine kinase inhibitor with selectivity for the epidermal growth factor receptor signal transduction pathway and potent in vivo antitmuor activity. It may offer therapeutic agents for the treatment of hyperproliferative diseases. | | Definition | ChEBI: 4,5-dianilinophthalimide is phthalimide substituted at the 4- and 5-positions by anilino groups. It has a role as a tyrosine kinase inhibitor and a geroprotector. | | Biochem/physiol Actions | DAPH is an inhibitor of Aβ fibril formation; Protein tyrosine kinase inhibitor, specific for EGFR. | | in vivo | CGP52411 (3.2 mg/kg, 6.3 mg/kg, 12.5 mg/kg, 25 mg/kg, and 50 mg/kg; oral administration; daily; for 15 days; female BALB/c nude mice) treatment in vivo against xenografts of the A431 and SK-OV-3 tumors, and has antitumor activity[1]. | Animal Model: | Female BALB/c nude mice injected with A431cells[1] | | Dosage: | 3.2 mg/kg, 6.3 mg/kg, 12.5 mg/kg, 25 mg/kg, and 50 mg/kg | | Administration: | Oral administration; daily; for 15 days | | Result: | Antitumor efficacy was obtained at doses between 50 mg/kg and 6.3 mg/kg.
|
| | IC 50 | EGFR: 0.3 μM (IC50); Amyloid-β |
| | DAPH Preparation Products And Raw materials |
|